Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, Zantac
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
GSK shares jump on $2.2 billion Zantac settlement
By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future growth persist as challenges with its drug pipeline remain.
18h
on MSN
GSK Bought More Shares of Biotech Wave Life Sciences
GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...
5h
GlaxoSmithKline (GSK) Gets a Hold from Kepler Capital
In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...
2d
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
Thanks largely to news of a crucial legal settlement, GSK ( GSK 5.84%) was one of the better-performing big pharma stocks on Wednesday. Relieved investors showed their appreciation by collectively ...
FiercePharma
2d
GSK will pony up $2.2B to resolve 80K Zantac cases
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
2d
FTSE 100 opens higher on GSK boost
The UK's benchmark FTSE 100 opened higher on Thursday, led by gains in GSK following the settlement of lawsuits in the United ...
1d
GSK’s problem is it has more than one source of pain
Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain ...
1d
GSK: The Worst Is Finally Over (Rating Upgrade)
GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...
1d
FTSE 100 Live 10 October: GSK shares rise on $2.2bn Zantac settlement, property firm gets £1.1bn bid
GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Zantac
GlaxoSmithKline
Inflation
RSV
United States
Feedback